[go: up one dir, main page]

PE20180687A1 - Reactivos quirales para la preparacion de oligomeros homogeneos - Google Patents

Reactivos quirales para la preparacion de oligomeros homogeneos

Info

Publication number
PE20180687A1
PE20180687A1 PE2018000192A PE2018000192A PE20180687A1 PE 20180687 A1 PE20180687 A1 PE 20180687A1 PE 2018000192 A PE2018000192 A PE 2018000192A PE 2018000192 A PE2018000192 A PE 2018000192A PE 20180687 A1 PE20180687 A1 PE 20180687A1
Authority
PE
Peru
Prior art keywords
preparation
chiral reagents
diastereomerically pure
benzyl
alkyl
Prior art date
Application number
PE2018000192A
Other languages
English (en)
Inventor
Atsushi Endo
Robert T Yu
Francis Fang
Hyeong Wook Choi
Mingde Shan
Original Assignee
Eisai Randd Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Randd Man Co Ltd filed Critical Eisai Randd Man Co Ltd
Publication of PE20180687A1 publication Critical patent/PE20180687A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS FOSFORAMIDOCLORIDATO MORFONILO NUCLEOSIDOS ACTIVADOS DIASTEREOMERICAMENTE PUROS DE FORMULA (20), (22), (25), ENTRE OTROS, DONDE R1 Y R2 SON CADA UNO H, ALQUILO C1-C3, FENILO, ENTRE OTROS; R3 ES TRITILO OPCIONALMENTE SUSTITUIDO, BENCILO, DIFENILMETILO, ENTRE OTROS; R4 Y R5 SON CADA UNO -H, -C(O)R7 O C(O)OR7, EN DONDE R7 ES ALQUILO C1-C6, BENCILO, ENTRE OTROS. TAMBIEN SE REFIERE A UN METODO DE PREPARACION Y UNA COMPOSICION QUE COMPRENDE UN OLIGOMERO DIASTEREOMERICAMENTE PURO
PE2018000192A 2015-08-05 2016-08-05 Reactivos quirales para la preparacion de oligomeros homogeneos PE20180687A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562201510P 2015-08-05 2015-08-05

Publications (1)

Publication Number Publication Date
PE20180687A1 true PE20180687A1 (es) 2018-04-23

Family

ID=56943909

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2023000140A PE20231843A1 (es) 2015-08-05 2016-08-05 Reactivos quirales para la preparacion de oligomeros homogeneos
PE2018000192A PE20180687A1 (es) 2015-08-05 2016-08-05 Reactivos quirales para la preparacion de oligomeros homogeneos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2023000140A PE20231843A1 (es) 2015-08-05 2016-08-05 Reactivos quirales para la preparacion de oligomeros homogeneos

Country Status (31)

Country Link
US (4) US10457698B2 (es)
EP (2) EP3331891B1 (es)
JP (4) JP6978406B2 (es)
KR (2) KR20250005537A (es)
CN (3) CN108350005B (es)
AU (3) AU2016302009B2 (es)
CA (1) CA2994842A1 (es)
CL (1) CL2018000322A1 (es)
CO (1) CO2018001615A2 (es)
CY (1) CY1125552T1 (es)
DK (1) DK3331891T3 (es)
ES (2) ES2993126T3 (es)
HR (1) HRP20220129T1 (es)
HU (2) HUE057593T2 (es)
IL (3) IL284611B2 (es)
LT (1) LT3331891T (es)
MA (1) MA44209B1 (es)
MD (1) MD3331891T2 (es)
MX (2) MX389022B (es)
MY (1) MY196627A (es)
NZ (2) NZ778828A (es)
PE (2) PE20231843A1 (es)
PH (1) PH12018500265A1 (es)
PL (1) PL3331891T3 (es)
PT (1) PT3331891T (es)
RS (1) RS62930B1 (es)
SI (1) SI3331891T1 (es)
SM (1) SMT202200089T1 (es)
UA (1) UA123995C2 (es)
WO (1) WO2017024264A2 (es)
ZA (3) ZA201801518B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3331891T2 (ro) 2015-08-05 2022-04-30 Eisai R&D Man Co Ltd Procedeu de obţinere a unui oligomer de fosforodiamidat substanțial diastereomeric pur, a unui oligomer de fosforodiamidat obţinut printr-un astfel de procedeu și a unei compoziții farmaceutice care conţine un astfel de oligomer de fosforodiamidat
WO2018057430A1 (en) 2016-09-20 2018-03-29 The Regents Of The University Of Colorado, A Body Corporate Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry
CN118109469A (zh) 2019-12-26 2024-05-31 日本新药株式会社 诱导外显子50的跳读的反义核酸
PE20230237A1 (es) 2020-02-28 2023-02-07 Nippon Shinyaku Co Ltd Acidos nucleicos antisentido que inducen la omision del exon 51
US20220195437A1 (en) 2020-12-11 2022-06-23 Eisai R&D Management Co., Ltd. Tau-targeting oligonucleotide gapmers
IL303504A (en) 2020-12-11 2023-08-01 Eisai R&D Man Co Ltd Poly-morpholino oligonucleotide gapmers
BR112023022514A2 (pt) 2021-04-28 2024-01-23 Eisai R&D Man Co Ltd Oligonucleotídeos antissenso e seu uso para tratamento de distúrbios neurodegenerativos
CA3259881A1 (en) * 2022-07-07 2024-01-11 Eisai R&D Man Co Ltd CRYSTALLINE MONOMERS FOR THE PREPARATION OF ANTISENSE OLIGONUCLEOTIDES AND THEIR PROCESSES FOR PREPARATION AND USE
TW202432183A (zh) 2022-10-27 2024-08-16 日商衛材R&D企管股份有限公司 肽—反義寡核苷酸及其用於治療神經退行性障礙之用途
WO2024163762A2 (en) * 2023-02-01 2024-08-08 Alnylam Pharmaceuticals, Inc. Six membered ring containing oligomers

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185444A (en) * 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US6117993A (en) * 1995-05-23 2000-09-12 Hybridon, Inc. Synthons for oligonucleotide synthesis
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5874554A (en) * 1996-12-13 1999-02-23 Incyte Pharmaceuticals, Inc. Methods and solvent vehicles for reagent delivery in oligonucleotide synthesis using automated pulse jetting devices
US6306599B1 (en) * 1999-07-16 2001-10-23 Agilent Technologies Inc. Biopolymer arrays and their fabrication
EP1176151B1 (en) * 2000-07-28 2014-08-20 Agilent Technologies, Inc. Synthesis of polynucleotides using combined oxidation/deprotection chemistry
AR036122A1 (es) 2001-07-03 2004-08-11 Avecia Biotechnology Inc Un complejo de sal que comprende un n-alquilimidazol y una 1,1-dioxo-1,2-dihidro-1l6-benzo [d]-isotiazol-3-ona y un metodo para sintetizar oligonucleotidos utilizando la quimica de fosforamidita
DK2207779T3 (da) * 2007-11-15 2014-07-14 Sarepta Therapeutics Inc Fremgangsmåde til syntese af morpholinooligomerer
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
WO2011018798A2 (en) 2009-08-14 2011-02-17 Indian Association For The Cultivation Of Science Morpholino-based antisense agent
AU2011257980B2 (en) * 2010-05-28 2016-06-30 Sarepta Therapeutics, Inc. Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
CA2813183C (en) 2010-09-30 2017-09-19 Nippon Shinyaku Co., Ltd. Morpholino nucleic acid derivatives
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
JP6478632B2 (ja) * 2011-05-05 2019-03-06 サレプタ セラピューティクス， インコーポレイテッド ペプチドオリゴヌクレオチドコンジュゲート
HK1202111A1 (en) 2011-11-18 2015-09-18 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
ES2832531T3 (es) 2011-11-30 2021-06-10 Sarepta Therapeutics Inc Oligonucleótidos para el tratamiento de enfermedades por expansión de repeticiones
CN102702265A (zh) * 2012-05-14 2012-10-03 天津特安化学科技有限公司 一种固相合成磷酰二胺吗啉代寡核苷酸及方法
PT2764002T (pt) 2014-04-11 2018-05-16 Gilead Sciences Inc Métodos para a preparação de análogos de nucleótidos anti-virais
GB201513921D0 (en) 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
EP3331563B1 (en) 2015-08-05 2023-04-19 Janssen Biotech, Inc. Anti-cd154 antibodies and methods of using them
DE102015214943A1 (de) 2015-08-05 2017-02-09 Siemens Aktiengesellschaft Verfahren und Anlage für eine chemische Synthese
MD3331891T2 (ro) * 2015-08-05 2022-04-30 Eisai R&D Man Co Ltd Procedeu de obţinere a unui oligomer de fosforodiamidat substanțial diastereomeric pur, a unui oligomer de fosforodiamidat obţinut printr-un astfel de procedeu și a unei compoziții farmaceutice care conţine un astfel de oligomer de fosforodiamidat

Also Published As

Publication number Publication date
HUE067910T2 (hu) 2024-11-28
MA44209A (fr) 2021-04-28
US20210171555A1 (en) 2021-06-10
MY196627A (en) 2023-04-23
WO2017024264A8 (en) 2018-04-12
CY1125552T1 (el) 2024-02-16
MX389022B (es) 2025-03-20
RS62930B1 (sr) 2022-03-31
IL293066A (en) 2022-07-01
CL2018000322A1 (es) 2018-05-18
EP4039690C0 (en) 2024-07-17
IL257353B2 (en) 2023-02-01
JP2025090640A (ja) 2025-06-17
IL284611B1 (en) 2023-07-01
AU2016302009A1 (en) 2018-03-29
PE20231843A1 (es) 2023-11-21
PH12018500265A1 (en) 2018-08-13
HUE057593T2 (hu) 2022-05-28
IL284611A (en) 2021-08-31
WO2017024264A3 (en) 2017-03-30
ZA201801518B (en) 2020-10-28
US20200115405A1 (en) 2020-04-16
CN108350005A (zh) 2018-07-31
EP3331891B1 (en) 2021-12-15
JP7254869B2 (ja) 2023-04-10
EP4039690A1 (en) 2022-08-10
DK3331891T3 (da) 2022-02-28
SI3331891T1 (sl) 2022-04-29
KR102788397B1 (ko) 2025-04-01
NZ778825A (en) 2024-11-29
HRP20220129T1 (hr) 2022-04-15
IL257353A (en) 2018-04-30
AU2016302009B2 (en) 2021-09-30
JP2018525380A (ja) 2018-09-06
CN113461733A (zh) 2021-10-01
UA123995C2 (uk) 2021-07-07
IL284611B2 (en) 2023-11-01
SMT202200089T1 (it) 2022-03-21
BR112018002430A2 (pt) 2018-09-18
IL257353B (en) 2022-10-01
MX2018001557A (es) 2018-05-02
RU2018107663A3 (es) 2020-05-21
AU2023226763B2 (en) 2025-09-18
US20250171475A1 (en) 2025-05-29
WO2017024264A2 (en) 2017-02-09
ES2907629T3 (es) 2022-04-25
MA44209B1 (fr) 2022-03-31
KR20180044303A (ko) 2018-05-02
PL3331891T3 (pl) 2022-03-28
ZA202201010B (en) 2024-05-30
AU2021290235A1 (en) 2022-01-20
CN117924364A (zh) 2024-04-26
JP2023085402A (ja) 2023-06-20
EP3331891A2 (en) 2018-06-13
MD3331891T2 (ro) 2022-04-30
AU2023226763A1 (en) 2023-09-28
CA2994842A1 (en) 2017-02-09
ZA201905394B (en) 2022-07-27
JP7712975B2 (ja) 2025-07-24
JP6978406B2 (ja) 2021-12-08
CN108350005B (zh) 2024-02-06
ES2993126T3 (en) 2024-12-23
EP4039690B1 (en) 2024-07-17
US10457698B2 (en) 2019-10-29
HK1248708A1 (zh) 2018-10-19
RU2018107663A (ru) 2019-09-05
KR20250005537A (ko) 2025-01-09
US20180222932A1 (en) 2018-08-09
BR122023025447A2 (pt) 2024-01-16
CO2018001615A2 (es) 2018-07-19
NZ740490A (en) 2024-07-05
JP2022003067A (ja) 2022-01-11
AU2021290235B2 (en) 2023-06-08
PT3331891T (pt) 2022-02-28
US10836784B2 (en) 2020-11-17
LT3331891T (lt) 2022-02-25
NZ778828A (en) 2024-11-29
MX2022000124A (es) 2022-02-16

Similar Documents

Publication Publication Date Title
PE20180687A1 (es) Reactivos quirales para la preparacion de oligomeros homogeneos
CL2018003504A1 (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplasicos.
CO2017008403A2 (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
PE20180024A1 (es) Triazolopirazinonas como inhibidores de pde1
UY36838A (es) Compuestos heterocíclicos moduladores de la señalización de tnf alfa y composiciones farmacéuticas que los contienen
ES2770058T3 (es) Compuestos y composiciones destinados a modular las actividades de quinasa de EGFR mutante
PE20190326A1 (es) Isoquinolin-3-il-carboxamidas y preparacion y uso de las mismas
EP3727401A4 (en) CYCLIC DI-NUCLEOTIDE COMPOUNDS AS STING AGONISTS
ES2723355T3 (es) Métodos útiles en la síntesis de análogos de halicondrina B
EA201792503A1 (ru) Соль (s)-kck s-кетамина, соль (r)-kck s-кетамина и способы получения s-кетамина
EA201692309A1 (ru) Стереохимически обогащенные композиции для доставки нуклеиновых кислот
CU20170164A7 (es) Compuestos n-tieno (2,3-d)pirimidinil-d-fenilalanina, método para preparar los mismos y composiciones farmacéuticas que los contienen
EA201890648A2 (ru) Диоксолановые аналоги уридина для лечения рака
PE20200342A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue
CO2017008600A2 (es) Análogos de desacetoxitubulisina h, composiciones y método de producción de los mismos
DOP2017000120A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
PE20180121A1 (es) Imidazopirazinonas como inhibidores de pde1
PE20211780A1 (es) Compuestos de pirimidinodiona biciclicos sustituidos con tetrahidropirano (thp)
EA201790570A1 (ru) Модуляторы р2х7
CR20170005A (es) Derivados de insoindolina
PE20190964A1 (es) Inhibidores de dopamina-b-hidroxilasa penetrantes de la barrera hematoencefalica
EA201792156A1 (ru) Ксантинзамещенные алкинилкарбаматы/обращенные карбаматы в качестве антагонистов a
EA201791645A1 (ru) Новые соли и полиморфы scy-078
MX386501B (es) Compuestos terapeuticos y sus metodos de uso
PE20161380A1 (es) Quinazolin-thf-aminas halogenadas como inhibidores de pde1